Lantern Pharma Inc., a clinical-stage oncology company leveraging artificial intelligence to develop precision cancer therapies, has announced a notable case of durable complete response in its ongoing Phase 2 HARMONIC™ clinical trial evaluating LP-300 for advanced non-small cell lung cancer (NSCLC).
